作者
Mansoor Raza Mirza,Bradley J. Monk,Jørn Herrstedt,Amit M. Oza,Sven Mahner,Andrés Redondo,Michel Fabbro,Jonathan A. Ledermann,Domenica Lorusso,Ignace Vergote,Noa Ben-Baruch,Christian Marth,Radosław Mądry,René dePont Christensen,Jonathan S. Berek,Anne Dørum,Anna V. Tinker,Andreas du Bois,Antonio González-Martín,Philippe Follana,Benedict B. Benigno,Per Rosenberg,Lucy Gilbert,B.J. Rimel,Joseph Buscema,John Balser,Shefali Agarwal,Ursula A. Matulonis
摘要
Niraparib is an oral poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer.
PDF的下载单位、IP信息已删除
(2025-6-4)
null
无极微光
吃葡萄不吐葡萄皮
Criminology34
学霸业
GingerF
渡人舟
Gp1983
Elsevier大王
My_magnum_opus
MchemG
sanvva
Chinno
v0id
deli
OK
Nole
华无剑
李小白
lx
皖公网安备34019202002308
